DSKYF
Daiichi Sankyo Company, Limited
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
18.00
■ 0.00 (0.00%)
MARKET · —
Price
Open
18.00
Prev close
18.00
Day high
17.40
Day low
17.40
Volume
1.30K
Market cap
—
P/E (TTM)
—
52W range
13.85 – 29.15
Trailing performance
Returnvs SPY
1W
+9.69%
+11.1%
1M
+2.74%
-1.0%
3M
+2.97%
-0.1%
6M
-3.33%
-14.4%
YTD
-16.28%
-28.6%
1Y
-29.16%
-49.2%
3Y
-37.00%
-111.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.12
+5.13% from price
SMA 20
17.02
+5.78% from price
SMA 50
16.58
+8.57% from price
SMA 100
16.78
+7.24% from price
SMA 200
18.74
-3.94% from price
EMA 12
17.26
+4.31% from price
EMA 26
16.99
+5.93% from price
EMA 50
16.85
+6.81% from price
RSI (14)
58.3
Neutral
MACD (12,26,9)
0.26
Hist 0.12
ATR (14)
0.71
3.97% of price
Realised vol 30D
77.3%
Annualised
Bollinger upper
18.37
20, 2σ
Bollinger lower
15.66
20, 2σ
50 / 200 cross
Death
16.58 vs 18.74
Trend bias
Below 200
-3.94%
Risk profile
Beta vs SPY
0.43
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
77.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.9%
Peak to trough
Max drawdown 5Y
-66.8%
Peak to trough
ATR 14
0.71
3.97% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term
GlobeNewswire · 2d ago
European Indexes Mixed, Autos Rally
The Wall Street Journal · 3d ago
Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca
GlobeNewswire · 5d ago
Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Business Wire · 6d ago
Does Daiichi Sankyo Company (TSE:4568) Have A Bigger Oncology Opening In China And Europe?
Simply Wall St. · 8d ago
European Indexes Mostly Lower as Middle East Tensions Weigh
The Wall Street Journal · 11d ago
Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Pharmaceutical Technology · 12d ago
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
PR Newswire · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.